For decades, Alzheimer’s treatment followed a familiar script: diagnose the disease, prescribe medication to manage symptoms, and prepare for decline. Precision medicine is rewriting that script by asking a different question — not just “what drug treats this?” but “why is this person’s brain declining?”
A precision-medicine approach uses comprehensive testing to identify the specific biological drivers behind each individual’s cognitive decline, then builds a personalized plan targeting those factors. The leading framework in this space is the ReCODE Protocol, developed by Dr. Dale Bredesen and delivered through Apollo Health. Below, we explain how it works, what the research shows, and how it is delivered as a residential program at Michigan Cognitive Recovery Center in Fort Gratiot, Michigan.
Quick Facts
| What it is: A multimodal, personalized approach to early-stage cognitive decline that addresses the underlying biological drivers, not just the symptoms.Leading protocol: ReCODE+ For Facilities Program (™), developed by Dr. Dale Bredesen and delivered through Apollo Health.Best for: Adults with subjective cognitive impairment (SCI), mild cognitive impairment (MCI), or early-stage Alzheimer’s who are medically stable.What the research shows: 75–84% improvement across two published studies; 90% improvement in the 2025 randomized controlled trial; an effect size 600% greater than the leading FDA-approved Alzheimer’s drug, according to Apollo Health.In Michigan: Michigan Cognitive Recovery Center at Lakeshore Woods Senior Living — 4851 Lakeshore Rd, Fort Gratiot Township, MI 48059. One of only two U.S. facilities offering the ReCODE+ For Facilities Program. 810-385-3185. |
What Is Precision Medicine for Alzheimer’s Disease?
Precision medicine for Alzheimer’s takes a different path than conventional treatment. Instead of giving everyone the same medication, it begins with comprehensive metabolic, genetic, and biomarker profiling — and uses the results to build a tailored intervention for each person.
The central question changes from “what drug treats Alzheimer’s?” to “why is this person’s brain declining, and what can we do about those specific factors?”
Dr. Dale Bredesen’s ReCODE Protocol — developed and delivered through Apollo Health — is the leading precision-medicine framework for Alzheimer’s. According to Apollo Health, the protocol identifies and addresses six categories of biological contributors to cognitive decline:
- Inflammation
- Lack of hormones and nutrients
- Metabolic dysfunction
- Toxin exposures
- Vascular dysfunction
- Traumatic brain injuries
The protocol uses extensive testing to identify which of these contributors are active in each person, then builds a personalized care plan — the ReCODE Report™ — that targets those specific drivers.
The three pillars of a precision-medicine approach
- Personalized testing: Comprehensive lab work and cognitive assessments establish a baseline for each individual.
- Root-cause identification: Testing reveals the specific biological drivers behind that person’s decline.
- Multimodal treatment: Multiple factors are addressed at once through nutrition, lifestyle, and targeted clinical interventions.
How Standard Alzheimer’s Treatment Falls Short for Early-Stage Patients
Conventional Alzheimer’s treatment typically offers symptomatic medications. Drugs like donepezil and memantine can help with daily functioning and may modestly slow decline. Newer FDA-approved anti-amyloid therapies like lecanemab can slow disease progression by removing amyloid plaques. None of these medications, however, address the multiple underlying drivers of decline.
Two challenges follow from this. First, the standard approach treats Alzheimer’s as if it has one cause, when research increasingly shows it is multi-factorial. Second, conventional treatment often begins after significant brain damage has already occurred, when the window for meaningful intervention has narrowed considerably.
- Focuses on managing symptoms rather than addressing causes.
- Single-target drug approach does not account for the multi-factorial nature of cognitive decline.
- Does not account for individual biological variation.
- Often misses the window when intervention could be most effective.
Why Early-Stage Alzheimer’s Is the Right Window for Precision Medicine
The earlier someone intervenes, the more options they have. In early stages, the brain retains more neuroplasticity — the brain’s ability to form new connections and adapt to change.
What do “early stages” actually mean?
- Subjective Cognitive Impairment (SCI): Self-noticed memory concerns that don’t yet show up on standard tests.
- Mild Cognitive Impairment (MCI): Measurable cognitive changes that don’t significantly interfere with daily life.
- Early-stage Alzheimer’s: Diagnosed disease, but the person still functions relatively independently.
All three represent critical windows where precision-medicine interventions may have the greatest impact, before irreversible structural damage accumulates in the brain.
Root Causes and Biological Drivers Targeted by Precision Medicine
Cognitive decline rarely comes from a single source. Apollo Health’s framework groups the contributors into six categories that precision-medicine testing investigates in each person.
Inflammation and immune activation
Chronic inflammation in the brain — neuroinflammation — is a significant driver of cognitive decline. Sources vary widely: hidden infections, poor gut health, or autoimmune responses that keep the immune system constantly activated. Persistent inflammation damages brain cells over time.
Metabolic dysfunction and insulin resistance
Insulin resistance in the brain — a phenomenon researchers sometimes informally call “Type 3 diabetes,” though it is not a formal medical diagnosis — impairs the brain’s ability to use glucose for energy. The brain is an energy-hungry organ, and when it can’t access fuel properly, it struggles to function. Metabolic dysfunction often appears years before memory symptoms become noticeable.
Toxic exposures and mycotoxins
Environmental toxins can contribute to cognitive decline in ways that often go unrecognized. Mycotoxins — toxic compounds produced by certain molds — heavy metals like mercury and lead, and various chemical exposures can all affect brain function. Many people don’t realize they’ve been exposed; someone might live or work in a building with hidden mold for years without connecting it to their cognitive symptoms.
Hormonal and nutrient deficiencies
Thyroid hormones, sex hormones (estrogen, testosterone, progesterone), vitamin D, and B vitamins all affect brain function. Deficiencies in any of these can accelerate cognitive decline. Standard medical evaluations often overlook these factors, or test for them but use reference ranges that miss subtle deficiencies.
Vascular and structural contributors
Reduced blood flow to the brain limits oxygen and nutrient delivery. Cardiovascular health and brain health are closely connected — which is why heart-disease risk factors also raise dementia risk. Sleep apnea, which interrupts breathing during sleep, contributes to cognitive decline through repeated oxygen deprivation, and many people who have it are undiagnosed.
Traumatic brain injuries
A history of head injuries — even those that seemed minor at the time — can contribute to long-term cognitive vulnerability. Apollo Health includes traumatic brain injury as a separate biological contributor that precision-medicine testing investigates.
Subtypes of Alzheimer’s Disease Identified Through Precision Medicine
Dr. Bredesen’s research identifies distinct subtypes of Alzheimer’s based on the primary biological driver. Understanding which subtype applies helps guide personalized treatment, because what works for one subtype may not work for another. The four most commonly described subtypes are summarized below.
| Subtype | Primary driver | Common markers |
| Inflammatory | Chronic infection or immune activation | Elevated inflammatory markers (e.g., C-reactive protein) |
| Atrophic | Hormone or nutrient withdrawal | Low hormone levels, vitamin and nutrient deficiencies |
| Toxic | Toxin exposure | History of mold exposure, elevated heavy metals |
| Vascular | Reduced blood flow | Cardiovascular risk factors, history of heart disease |
Inflammatory subtype
Involves chronic immune activation, often from infections or inflammatory conditions. People with this subtype may show elevated C-reactive protein or other inflammatory markers in their blood work.
Atrophic subtype
Results from a lack of trophic support — meaning the hormones, nutrients, and growth factors the brain relies on to maintain itself. Often appears in people with multiple deficiencies.
Toxic subtype
Linked to biotoxin or chemical exposure. People with this subtype often have a history of mold exposure or elevated heavy-metal levels, and can present differently on cognitive testing than other subtypes.
Vascular subtype
Connects to cardiovascular and cerebrovascular health. Risk factors include high blood pressure, diabetes, and a history of heart disease.
Diagnostic Workup Used in Precision Medicine for Early-Stage Alzheimer’s
Comprehensive testing establishes a baseline and identifies individual contributors. Families considering precision medicine for early-stage Alzheimer’s can expect a thorough evaluation process that goes well beyond standard memory testing.
Cognitive and neuropsychological testing
Standardized cognitive assessments measure baseline function and track changes over time. Tools like the Montreal Cognitive Assessment (MoCA) evaluate memory, attention, language, and executive function. These tests provide objective data points that can be compared across the program.
Blood-based and cerebrospinal fluid biomarkers
Blood tests evaluate inflammation, metabolic markers, hormones, nutrients, and toxins. Biomarkers are measurable indicators of biological processes, and they reveal which contributors are active in each person. The workup is extensive — well beyond a standard blood panel.
MRI volumetry and neuroimaging
Brain imaging measures brain volume and identifies areas of atrophy. Volumetric MRI can track structural changes over time, showing whether interventions are helping preserve brain tissue. This provides objective evidence beyond cognitive test scores.
Genetic testing and APOE status
The APOE4 gene variant increases Alzheimer’s risk, but genes are not destiny. Knowing APOE status helps inform personalized strategies. People with APOE4 may benefit from earlier and more aggressive intervention, and certain lifestyle factors — particularly the KetoFLEX 12/3 nutrition pattern — may be especially important for them.
Personalized Treatment: The Bredesen Seven
Treatment in a precision-medicine model addresses multiple contributors at once. Apollo Health refers to the seven complementary strategies as the Bredesen Seven — the curriculum at the heart of the ReCODE Protocol. For a deeper look at one of these pillars, see our companion guide to the KetoFLEX 12/3 diet.
1. Nutrition (KetoFLEX 12/3)
A plant-rich, mildly ketogenic eating pattern with time-restricted eating — a minimum 12-hour overnight fast and at least 3 hours between dinner and bedtime. Supports metabolic health and provides ketones as alternative brain fuel when glucose metabolism is impaired.
2. Exercise
Aerobic and strength training increase blood flow to the brain and promote neuroplasticity. Regular movement also improves insulin sensitivity and reduces inflammation. The type and intensity are tailored to each person’s abilities and health status.
3. Sleep optimization
During deep sleep, the brain’s glymphatic system clears waste products including the amyloid proteins associated with Alzheimer’s. Poor sleep means poor brain cleanup. Addressing sleep apnea and improving sleep quality directly support brain detoxification — and for many people, sleep optimization becomes one of the most impactful interventions.
4. Stress management
Chronic stress elevates cortisol, which can damage the hippocampus, the brain’s memory center. Meditation, breathing practices, and social connection help regulate the stress response. The goal isn’t eliminating stress — it’s building the capacity to recover from it.
5. Brain stimulation
Cognitive training exercises help build new neural pathways. Neuroplasticity — the brain’s ability to reorganize and form new connections — remains possible even after cognitive decline has begun. The brain can still learn and adapt, though it may take more focused effort.
6. Detoxification
When toxin exposure is identified as a contributor, specific protocols help reduce the toxic burden. This may include addressing mold in the home environment or supporting the body’s natural detoxification pathways through targeted interventions.
7. Targeted supplements
Supplements and hormone support are tailored to individual deficiencies identified in testing. What one person needs may be completely different from what another needs — generic supplement protocols miss the point of precision medicine.
How Anti-Amyloid Drugs Fit Alongside Precision Medicine
FDA-approved anti-amyloid drugs like lecanemab (Leqembi) and donanemab (Kisunla) target and remove amyloid plaques from the brain. These medications represent a real advance in Alzheimer’s treatment, and they can modestly slow disease progression. They address only one piece of a complex puzzle, however.
- What anti-amyloid drugs do: target and remove amyloid protein plaques from the brain.
- What they don’t address: inflammation, metabolic dysfunction, toxins, hormonal imbalances, vascular issues, and other root causes.
- How they can work together: precision medicine addresses the multifactorial contributors that drugs alone don’t target.
For some families, combining both approaches under physician guidance may offer the most comprehensive strategy. Treatment decisions should be made with a qualified healthcare provider.
What the Research Shows About Precision Medicine Outcomes
Published peer-reviewed studies on the ReCODE Protocol have documented cognitive improvement in participants with mild cognitive impairment (MCI) and early-stage Alzheimer’s.
- Two published clinical studies have reported that 75–84% of participants with MCI or early-stage dementia experienced measurable improvement in cognition while following the protocol.
- A 2025 randomized controlled trial — the first of its kind for ReCODE — found statistically significant improvements in memory, executive function, processing speed, and overall cognition. According to Apollo Health, the trial reported 90% of participants showing cognitive improvement and an effect size 600% greater than the leading FDA-approved Alzheimer’s drug. Participants also showed improvements in blood pressure, insulin sensitivity, and cholesterol.
- MRI volumetry has shown brain-volume stabilization in some participants — significant given that brain atrophy typically progresses in Alzheimer’s.
Results vary by individual and stage. Precision medicine for Alzheimer’s is not a cure. Earlier-stage participants tend to see the strongest results. For complete clinical information, please visit Apollo Health.
Who Is a Candidate for Precision Medicine for Early-Stage Alzheimer’s?
Precision-medicine programs work best for individuals in the earlier stages of cognitive decline who are medically stable and willing to participate in lifestyle changes.
- Subjective Cognitive Impairment (SCI) with noticeable memory concerns
- Mild Cognitive Impairment (MCI) diagnosis
- Early-stage Alzheimer’s disease
- Strong family history seeking proactive prevention
- Medically stable and able to participate in a structured program
Later-stage dementia may not see the same benefits, which is why early intervention matters so much. The window for meaningful change narrows as the disease progresses.
Choosing a Residential Precision-Medicine Program
Implementing a precision-medicine protocol at home can overwhelm families. The daily structure — nutrition, exercise, sleep optimization, brain stimulation, and ongoing monitoring — requires consistency that’s difficult to maintain without professional support.
Residential programs provide full daily implementation with trained staff, ongoing testing, and plan adjustments. Michigan Cognitive Recovery Center at Lakeshore Woods Senior Living in Fort Gratiot, Michigan operates a 12-month residential program — and is one of only two facilities in the United States offering the ReCODE+ For Facilities Program. The program combines the full clinical protocol with 24/7 dementia-care support.
What to look for in a residential program
- Apollo Health-trained practitioners and medical oversight
- Comprehensive diagnostic testing and personalized protocols
- Daily implementation of all seven Bredesen pillars
- Continuous monitoring and plan adjustments based on testing
- Trained dementia-care staff available around the clock
- Transparent communication with families about goals and outcomes
Precision Medicine for Alzheimer’s in Michigan
Michigan Cognitive Recovery Center serves families across Michigan from its Fort Gratiot location at 4851 Lakeshore Rd, including Port Huron, Marysville, Burtchville, Lexington, and the rest of St. Clair County, as well as families traveling from Macomb County, Oakland County, and metro Detroit. A second Michigan location is opening soon at Fenton Woods, expanding access for families in Fenton, Linden, Holly, Grand Blanc, Flint, and Genesee County.
To learn more about the residential precision-medicine program, see our guide to ReCODE residential care in Michigan or call 810-385-3185 to speak with the team and schedule a tour of the Birch Building at Lakeshore Woods.
Frequently Asked Questions
What vitamin is linked to a lower dementia risk?
B vitamins (especially B12 and folate) and vitamin D are commonly studied for their connection to brain health. A precision-medicine approach tests for individual deficiencies rather than recommending generic supplementation, because what matters is whether you are actually deficient.
What causes the majority of dementia cases?
Alzheimer’s disease is the most common cause of dementia. Precision-medicine research suggests there are multiple contributing factors rather than a single cause, which is why personalized approaches that address several drivers may be more effective than single-target treatments.
Can precision medicine be combined with FDA-approved drugs?
Yes. Precision medicine addresses root causes that anti-amyloid drugs do not target, making them potentially complementary. Treatment decisions should be made with a qualified physician.
How long does a precision-medicine protocol take to show results?
Most protocols are designed over 9 to 12 months. Some participants notice changes within the first few months, while others require longer to see measurable improvement. Individual results vary based on stage, contributors, and adherence.
Is precision medicine for Alzheimer’s covered by insurance?
Currently, most precision-medicine programs are not covered by insurance, though individual components like lab testing may have partial coverage. Families should check with their insurance providers about specific tests and services.
Is precision medicine for Alzheimer’s a cure?
No. Precision medicine is not a cure for Alzheimer’s disease. It is an evidence-based, personalized approach that has shown measurable cognitive improvement in published peer-reviewed studies, especially for participants in the earlier stages of cognitive decline.
Where is precision medicine for Alzheimer’s available in Michigan?
Michigan Cognitive Recovery Center at Lakeshore Woods Senior Living in Fort Gratiot is one of only two U.S. facilities offering the ReCODE+ For Facilities Program. A second Michigan location is opening soon at Fenton Woods. Call 810-385-3185 or visit michigancognitiverecovery.com to learn more.
Where can I learn more about the science behind precision medicine for Alzheimer’s?
For complete clinical information about the ReCODE Protocol and the science behind precision medicine for Alzheimer’s, please visit Apollo Health, the organization founded by Dr. Dale Bredesen that develops and oversees the protocol.
Ready to learn more? Call Michigan Cognitive Recovery Center at 810-385-3185 or visit michigancognitiverecovery.com to schedule a tour and learn how the residential ReCODE+ For Facilities Program supports families seeking a precision-medicine approach to early-stage cognitive decline.
Disclaimer: This content is for educational purposes only and does not constitute medical advice. Precision medicine for Alzheimer’s — including the ReCODE Protocol — is delivered by Apollo Health-trained practitioners and is not a cure for Alzheimer’s disease. Outcomes vary by individual. For complete clinical information about the ReCODE Protocol, please visit Apollo Health. Always consult a qualified healthcare provider before making treatment decisions.
About the author. This article was written by the Lakeshore Woods Team. Lakeshore Woods Senior Living is a 78-bed senior living community in Fort Gratiot Township, Michigan, and the home of Michigan Cognitive Recovery Center — one of only two U.S. senior living centers that offers the ReCODE+ For Facilities Program in partnership with Apollo Health. For complete clinical information about the ReCODE Protocol, please visit Apollo Health.